LearnGlossaryMarketStocksSuperinvestorsSign in

BBNX

Beta Bionics, Inc.

Healthcare · $968M market cap

Verdict

We can't put a fair value on BBNX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth189.1% a year✓
Free cash flow growth—?
Return on invested capital-31.4%✗

Follow BBNX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds BBNX right now. In Q2 2026, 1 sold out. Who we track

Moves in Q2 2026

Sold out: First Eagle Investment Management

Insider activity

Since Sep 2, 2026: no open-market purchases and 7 sales worth $1.5M. Why purchases matter

Sales

Hopman Mark

Chief Commercial Officer · 2026-09-09

Sold

$681K

Saint Sean

President & CEO · 2026-09-03

Sold

$113K

Saint Sean

President & CEO · 2026-09-02

Sold

$322K

Feider Stephen

Chief Financial Officer · 2026-09-02

Sold

$128K

Mensinger Mike

Chief Product Officer · 2026-09-02

Sold

$84K

Show all 7 sales

Russell Steven Jon

Chief Medical Officer · 2026-09-02

Sold

$81K

Hopman Mark

Chief Commercial Officer · 2026-09-02

Sold

$102K

About Beta Bionics, Inc.

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works